Ablacon
- Company typePublic
- Founded1979
- HeadquartersWheat Ridge, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
Ablacon firmographics
Firmographics- Name
- Ablacon
- Legal name
- Boston Scientific Corporation
- Website
- https://ablacon.com
- Company type
- Public
- Founded year
- 1979
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Ablacon industry classification
Industry- Product category
- Cardiac Electrophysiology Software
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro industry
- Electrophysiology Mapping & Ablation SystemsHealthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)Electrophysiology (Heart Rhythm)
Keywords
Where Ablacon is headquartered
LocationHeadquarters
- HQ city
- Wheat Ridge
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Ablacon business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Capital Equipment Sales: Sale of OPAL HDx Mapping System as capital equipment to hospitals and electrophysiology labs. Includes system components such as Signal Station, Workstation PC, Localization Generator, and System Cart.
- ExpertCare Service Plans: Prepaid service agreements providing 24-hour technical support, uptime guarantees, and cost control for electrophysiology systems
- Compatible Catheters and Consumables: Sales of compatible catheters including FARAWAVE NAV PFA Catheter, FARAPOINT PFA Catheter, INTELLAMAP ORION Mapping Catheter, and INTELLANAV STABLEPOINT Ablation Catheter
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Multi-year contract | OPAL HDx Mapping System - Capital Equipment |
| Subscription | Annual | ExpertCare Service Plans |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Ablacon product offering
Product offeringCore offering
Ablacon develops and provides AI-guided atrial fibrillation therapies that use computational analysis to map and target the electrical sources driving AF, supporting electrophysiologists performing cardiac ablation procedures. The offering combines proprietary AI algorithms with clinical workflow integration to identify ablation targets that conventional mapping may miss.
Product overview
No product information available for Ablacon in the provided source data. The source material contains information about Boston Scientific's OPAL HDx Mapping System and related cardiac electrophysiology products, but no data about Ablacon.
Differentiator
Problem solved
Functional benefit
Brands
- FARAPULSE: Pulsed Field Ablation (PFA) system for cardiac ablation procedures, including FARAWAVE NAV and FARAPOINT catheters.
- INTELLAMAP ORION
- INTELLANAV STABLEPOINT
- OPTIMAP
- FARAVIEW
- LUMIPOINT
- EDUCARE
- ExpertCare
Quantifiable outcome
- 0.2% catheter-related complication rate in DISRUPT-AF registry (n=477)
- +3 more outcomes
Companies that use Ablacon
Customer profileSegments2 records
Ideal customer profiles1 record
Ablacon technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Ablacon partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Cortex, Inc.coreBoston Scientific acquired the OPTIMAP System from Cortex, Inc., an advanced diagnostic mapping system that uses electrographic flow (EGF) algorithm to identify sources of atrial fibrillation. OPTIMAP will integrate with the OPAL HDx mapping system to strengthen Boston Scientific's integrated mapping and ablation portfolio.
Scale indicators3 records
Recent moves5 records
Expansion highlights5 records
Ablacon competitors and assessment
Company assessmentEmerging players
- CathVision: Develops AI-enabled electrophysiology recording and signal processing systems used during ablation procedures. Competes with Ablacon in applying software/AI to improve cardiac ablation workflow quality, though at the recording/analytics layer rather than mapping.
- Kardium: Developer of the Globe PF Mapping and Ablation System, a single-catheter pulsed field ablation solution for AF. Competes in the same ablation workflow where Ablacon's EGF mapping adds value, and shares the same target customer (electrophysiology labs performing AF procedures).
- Stereotaxis: Provides robotic magnetic navigation for catheter ablation procedures, integrating with mapping systems used in AF treatment. Adjacent to Ablacon's value proposition of improving precision in cardiac ablation, with partial overlap in electrophysiology lab equipment.
- Vektor Medical: Applies AI to standard 12-lead ECG data to non-invasively identify arrhythmia sources for ablation targeting. Adjacent competitor to Ablacon's EGF mapping approach, addressing the same clinical problem of pinpointing AF drivers from a different technological angle.
- Imricor Medical Systems: Focused on MRI-guided cardiac ablation, enabling real-time imaging during AF procedures. Competes with Ablacon in the same clinical workflow of mapping and ablating AF, but with a fundamentally different visualization modality.
Direct peers
- Medtronic: Major player in cardiac ablation with the CardioInsight mapping technology and pulsed field ablation systems. Competes directly with Ablacon's AF mapping approach and has comparable global commercialization scale in electrophysiology labs.
- Acutus Medical: Pioneered non-contact dipole density mapping for arrhythmia diagnosis and AF treatment. Competes with Ablacon in offering next-generation AI/algorithmic cardiac mapping to electrophysiologists, though at a smaller scale and with a narrower product line.
- Johnson & Johnson (Biosense Webster): The market-leading cardiac electrophysiology franchise, offering the CARTO 3 mapping system and a broad ablation catheter portfolio. Directly competes with Ablacon's EGF-guided mapping approach in the same electrophysiology labs and with overlapping physician customers.
- Abbott: Offers the EnSite X cardiac mapping system and a portfolio of ablation catheters for AF and complex arrhythmias. Competes head-to-head with Ablacon in cardiac mapping and ablation workflows, serving the same electrophysiologist customer base.
Broad incumbents
- Boston Scientific: Ablacon's underlying EGF/OPTIMAP technology is being integrated into Boston Scientific's OPAL HDx mapping platform following the 2024 acquisition of OPTIMAP from Cortex. Boston Scientific is both a potential commercialization partner and a strategic incumbent in the same clinical workflow.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights5 records
Customer concentration
Ablacon financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ablacon leadership team
Management profileNumber of profiles
Profiles6 records
Ablacon funding detail
Funding detailFunding overview
Funding rounds4 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ablacon M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ablacon
What does Ablacon do?
Ablacon develops and provides AI-guided atrial fibrillation therapies that use computational analysis to map and target the electrical sources driving AF, supporting electrophysiologists performing cardiac ablation procedures. The offering combines proprietary AI algorithms with clinical workflow integration to identify ablation targets that conventional mapping may miss.
Is Ablacon a public or private company?
Ablacon is a public company. It is classified as venture growth investor backed and is currently operating.
When was Ablacon founded?
Ablacon was founded in 1979. It employs 11 to 50 people.
Where is Ablacon based?
Ablacon is headquartered in Wheat Ridge, United States, in the North America region.
How does Ablacon make money?
Three revenue lines are on record. Capital Equipment Sales are the primary driver. The others are expertCare Service Plans and compatible Catheters and Consumables.
Who are Ablacon's main competitors?
Emerging players on record are CathVision, Kardium, Stereotaxis, Vektor Medical and Imricor Medical Systems. Direct peers are Medtronic, Acutus Medical, Johnson & Johnson (Biosense Webster) and Abbott. Boston Scientific is listed as a broad incumbent.
Does Ablacon have an API?
No public API is recorded for Ablacon.
What industry is Ablacon in?
Ablacon's product category is Cardiac Electrophysiology Software. Its primary akta.pro industry code is HLAHAFAD, Electrophysiology Mapping & Ablation Systems, with a secondary code of HLAKABAC, Electrophysiology (Heart Rhythm). Its NAICS code is 334510 and its SIC code is 3845.